Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
100%(6 trials)
Terminated
3(27%)

Phase Distribution

Ph phase_3
3
27%
Ph phase_2
7
64%

Phase Distribution

0

Early Stage

7

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
7(70.0%)
Phase 3Large-scale testing
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(6)
Terminated(4)
Other(1)

Detailed Status

Completed6
Terminated3
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 27 (70.0%)
Phase 33 (30.0%)

Trials by Status

unknown19%
completed655%
withdrawn19%
terminated327%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

NCT02612129
unknown

Early Access Program With Arimoclomol in US Patients With NPC

NCT04316637
terminatedphase_3

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

NCT04049097
completedphase_3

Arimoclomol in Amyotropic Lateral Sclerosis

NCT03491462
terminatedphase_3

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

NCT03836716
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02612129Phase 2

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

Completed
NCT04316637

Early Access Program With Arimoclomol in US Patients With NPC

Unknown
NCT04049097Phase 3

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

Terminated
NCT03491462Phase 3

Arimoclomol in Amyotropic Lateral Sclerosis

Completed
NCT03836716Phase 3

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Terminated
NCT02753530Phase 2

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Completed
NCT03746587Phase 2

Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Terminated
NCT00706147Phase 2

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

Completed
NCT00769860Phase 2

Arimoclomol in Sporadic Inclusion Body Myositis

Completed
NCT00561366Phase 2

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Withdrawn
NCT00244244Phase 2

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11